We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Get Up to $500 of Free Promega Reagents with our Back to the Bench Program. Register Now ›

Viral ToxGlo™ Assay

Determine Viral CPE or Monitor Compounds for Antiviral Activity

  • Easy, simple protocol measures ATP
  • Quantifiable assay for measuring viral-induced cytopathic effect (CPE)
  • Compatible with high-throughput screening

Size

Catalog number selected: G8941

$ 121.00
Your price:
Add to Cart
This product is discontinued
Add to Helix
Viral ToxGlo™ Assay
10ml
$ 121.00
Your price: Log in
Change Configuration

The Viral ToxGlo™ Assay is a simple, quantifiable method of determining viral-induced cytopathic effects (CPE) in host cells caused by lytic virions. The assay measures cellular ATP as a surrogate measure of host cell viability. When CPE occurs due to viral infection, ATP depletion can be measured and correlated with viral burden. The amount of ATP detected is directly proportional to the number of viable host cells in culture and can be used as a simple method to quantify viral-induced CPE. The homogeneous "add-mix-measure" assay procedure involves adding the single reagent (ATP Detection Reagent) directly to host cells following viral treatment. A “glow-type” luminescent signal is generated that is proportional to the amount of ATP present. Cell washing, multiple pipetting steps and visual assessment are not required to assess CPE. The system detects as few as 15 cells/well in a 384-well format in 10 minutes after reagent addition and mixing and is designed for use in multiwell formats, making it ideal for automated high-throughput screening (HTS).

Features and Benefits

Objectively Quantify CPE: The assay provides quantifiable data by luminescence detection, which obviates subjective operator error associated with visual scoring methods.

Decrease Time to Results: Data can be recorded and analysis begun 10 minutes after reagent addition.

Simplify Assessment of CPE: The homogeneous “add-mix-measure” protocol dramatically reduces the manual steps required for CPE assessment.

Choose Your Format: The reagent is scalable from 96- to 1536-well plate formats.

Amenable to High Throughput Screening: Luminescent signal is very stable with a half-life generally >5 hours dependent on cell type and medium used, allowing batch or consecutive processing. No fluorescence interference results in high signal to background and delivers excellent Z′ values in screening applications.

Applications include the determination of viral infectivity and the corresponding tissue culture infective dose (TCID50) and potential antiviral potency or off-target toxicity of test compounds.

This method is only useful for viruses that produce cytotoxicity and CPE.

Viral ToxGlo™ Assay reagent preparation and delivery.

Viral ToxGlo™ Assay reagent preparation and delivery.
Viral ToxGlo™ Assay reagent preparation and delivery.

              Quantifiable Measure of CPE

TCID50 determination.

TCID<sub>50</sub> determination.
TCID50 determination.

Increased luminescence indicates less infective virus and less CPE. Panel A. Dilutions of Influenza virus H1N1 were applied to MDCK monolayers. Panel B. Dilutions of VEEV applied to Vero E6 monolayers. Panel C. Dilutions of dengue virus applied to BHK-21 monolayers. Panel D. Dilutions of RSV applied to A549 monolayers. After incubation ATP Detection Reagent was added directly to cells and luminescence measured. 

Accurately Calculate Toxicity of Test Compounds

Fast and simple determination of antiviral potency.

Fast and simple determination of antiviral potency.
Fast and simple determination of antiviral potency.

Panel A. Test compound reduces viral CPE with no off-target cytotoxicity. MDCK cells with 100 TCID50 of H1N1 (on-target antiviral) or MDCK cells only (off-target cytotoxicity). Panel B. Test compound reduces viral CPE and also causes off-target cytotoxicity. BHK-21 cell monolayer with 100 TCID50 of Dengue virus (on-target antiviral) or BHK-1 cells only (off-target cytotoxicity). After incubation, ATP Detection Reagent was added directly to cells and luminescence measured.

Specifications

You are viewing: G8941 Change Configuration

What's in the box?

Item Part # Size

ATP Detection Buffer

G806A 1 × 10ml

ATP Detection Substrate

V363A 1 × 1 vial

SDS

Choose language:

Download SDSPDF (127 KB) – English (United States)

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

European Pat. No. 1131441 and Japanese Pat. No. 4520084.

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. Nos. 7,741,067, 8,361,739 and 8,603,767 and other patents and patents pending.

Specifications

You are viewing: G8942 Change Configuration

What's in the box?

Item Part # Size

ATP Detection Buffer

G806A 10 × 10ml

ATP Detection Substrate

V363A 10 × 1 vial

SDS

Choose language:

Download SDSPDF (127 KB) – English (United States)

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

European Pat. No. 1131441 and Japanese Pat. No. 4520084.

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. Nos. 7,741,067, 8,361,739 and 8,603,767 and other patents and patents pending.

Specifications

You are viewing: G8943 Change Configuration

What's in the box?

Item Part # Size

ATP Detection Buffer

G806B 1 × 100ml

ATP Detection Substrate

V363B 1 × 1 vial

SDS

Choose language:

Download SDSPDF (127 KB) – English (United States)

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Patents and Disclaimers

European Pat. No. 1131441 and Japanese Pat. No. 4520084.

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. Nos. 7,741,067, 8,361,739 and 8,603,767 and other patents and patents pending.

Let's find the product that meets your needs.

Talk to a Scientist

Joliene

Joliene

US